Sepiapterin reductase inhibition selectively reduces inflammatory joint pain and increases urinary sepiapterin

ConclusionSPR inhibition reduces pain associated with joint inflammation, showing potential utility as an analgesic strategy for inflammatory joint pain. SPR inhibition also increases urinary sepiapterin, indicating the potential of this measurement as a non ‐invasive biomarker of target engagement of SPR inhibitors, such as sulfasalazine (SSZ), a disease‐modifying anti‐rheumatic drug used as a first line treatment for rheumatoid arthritis (RA).This article is protected by copyright. All rights reserved.

Source: Arthritis and Rheumatology - July 26, 2019 Category: Rheumatology Authors: Masahide Fujita, D ébora da Luz Scheffer, Bruna Lenfers Turnes, Shane J. F. Cronin, Alban Latrémolière, Michael Costigan, Clifford J. Woolf, Alexandra Latini, Nick A. Andrews Tags: Full Length Source Type: research